<DOC>
	<DOCNO>NCT02767297</DOCNO>
	<brief_summary>To determine relative bioavailability capsule ( reference ) tablet ( test ) formulation FDL169 healthy adult male female , evaluate pharmacokinetic ( PK ) profile FDL169 tablet ( test formulation ) healthy adult male female , subject cystic fibrosis ( CF ) .</brief_summary>
	<brief_title>Bioavailability Pharmacokinetics Study FDL169 Healthy Subjects Subjects With Cystic Fibrosis</brief_title>
	<detailed_description>This three-part study . Part 1 : Part 1 study single dose , open-label , randomize crossover study healthy male female subject compare relative bioavailability two formulation FDL169 . Part 2 : Part 2 study multiple , escalate dose study three different dos test formulation FDL169 healthy male female subject evaluate PK profile test formulation FDL169 . Part 3 : Part 3 study single dose , open-label study male female subject CF determine PK profile test formulation FDL169 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Parts 1 2 : 1 . Healthy , males female 18 55 year age , inclusive , BMI &gt; 19 &lt; 30 kg/m2 . 2 . If sexually active , must meet contraception requirement . Part 3 : 1 . Male female subject age 18 year old . 2 . If sexually active , must meet contraception requirement . 3 . Diagnosis CF . 4 . History pancreatic insufficiency . 5 . Forced expiratory volume 1 second ( FEV1 ) ≥40 % predict normal age , sex height screen . Parts 1 2 : 1 . Prior ongoing medical condition , medical history , physical finding , ECG find laboratory abnormality could adversely affect safety subject . 2 . Alkaline phosphatase , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) level &gt; 1.5 x upper limit normal ( ULN ) screening . 3 . Use prescription nonprescription drug within 21 day five halflives ( whichever longer ) first dose study medication , unless medication interfere study procedure compromise subject safety . 4 . Pregnant nursing female . 5 . Serum creatinine total bilirubin &gt; 1.5 x ULN ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 6 . History prolong QT and/or QTcF interval . 7 . ECG single QTcF &gt; 450 msec male , &gt; 460 msec female , Screening . 8 . Positive urinary drug abuse screen Screening Day 1 , positive alcohol screen Day 1 . 9 . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit . 10 . History human immunodeficiency virus ( HIV ) positive HIV , hepatitis B hepatitis C result screen . 11 . Donation 500 mL blood within 3 month Day 1 . 12 . Participation clinical trial involve receipt investigational product within past 90 day exposure four new chemical entity 12 month first dose day . 13 . Current smoking use tobacco product substitute . Former smoker eligible , provide smoke least 6 month Day 1 . 14 . Use prescription nonprescription medication inhibitor inducer cytochrome P450 ( CYP ) 3A4 within 7 day Day 1 . Part 3 : 1 . History illness , ongoing acute illness could impact safety subject confound study result . 2 . Abnormal liver function ≥3 x ULN : AST , ALT , total bilirubin . 3 . A pulmonary exacerbation , change therapy pulmonary disease within 4 week prior Baseline ( Day 1 ) Visit 4 . Use herbal dietary supplement within 21 day five halflives ( whichever longer ) first dose study medication , unless medication interfere study procedure compromise subject safety . 5 . Pregnant nursing female . 6 . Serum creatinine total bilirubin &gt; 1.5 x ULN ( isolated bilirubin &gt; 1.5 x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 7 . History prolong QT and/or QTcF interval . 8 . ECG single QTcF &gt; 450 msec male , &gt; 460 msec female , Screening . 9 . Positive urinary drug abuse screen Screening Day 1 , positive alcohol screen Day 1 . 10 . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit . 11 . History HIV , positive HIV , hepatitis B hepatitis C result screen . 12 . Donation 500 mL blood within 3 month Day 1 . 13 . Participation clinical trial involve receipt investigational product within past 90 day exposure four new chemical entity 12 month first dose day . 14 . Current smoking use tobacco product substitute . Former smoker eligible , provide smoke least 6 month Day 1 . 15 . Use prescription nonprescription medication inhibitor inducer CYP3A4 , within 7 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>